CytoMed Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for CytoMed Therapeutics stock has a target of 5.00, which predicts an increase of 120.75% from the current stock price of 2.27.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$5.00	$5.00	$5.00	$5.00
Change	+120.75%	+120.75%	+120.75%	+120.75%

* Price targets were last updated on Oct 10, 2024.

Analyst Ratings

According to 1 stock analyst, the rating for CytoMed Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '25	Feb '25	Mar '25	Apr '25	May '25
Strong Buy	0	0	0	0	0
Buy	1	1	1	1	1
Hold	0	0	0	0	0
Sell	0	0	0	0	0
Strong Sell	0	0	0	0	0
Total	1	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Bruce Jackson Benchmark	Benchmark	Buy Reiterates $5	Buy	Reiterates	$5	+120.75%	Oct 10, 2024
Bruce Jackson Benchmark	Benchmark	Buy Reiterates $5	Buy	Reiterates	$5	+120.75%	Jun 11, 2024
Bruce Jackson Benchmark	Benchmark	Buy Reiterates $5	Buy	Reiterates	$5	+120.75%	Dec 4, 2023
Bruce Jackson Benchmark	Benchmark	Buy Initiates $5	Buy	Initiates	$5	+120.75%	Jul 21, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

530.40K

from 1.13M

-53.23%

from 1.13M

Revenue Next Year

n/a

from 530.40K

EPS This Year

-0.17

from -0.22

EPS Next Year

n/a

from -0.17

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025
Revenue	59.47K	113.84K	363.91K	507.74K	1.13M	530.40K
Revenue Growth	-	91.43%	219.67%	39.52%	123.34%	-53.23%
EPS	-0.33	-0.30	-0.40	-0.39	-0.22	-0.17
EPS Growth	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3

Financial currency is SGD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025
High	546,000
Avg	530,400
Low	509,600

Revenue Growth

Revenue Growth	2025
High	-51.9%
Avg	-53.2%
Low	-55.1%

EPS Forecast

EPS	2025
High	-0.18
Avg	-0.17
Low	-0.17

EPS Growth

EPS Growth	2025
High	-
Avg	-
Low	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.